Skip to content
value.today
Twist Bioscience Corp logo

Twist Bioscience Corp

Total raised
$258 M
6 rounds on record
Latest round
$50 M
Mar 2018
First round on record
Jul 2013
Today
Went public
See the company page

Twist Bioscience Corp is listed today as Twist Bioscience Corporation: market value, financials and filings are on its company page.

Funding rounds

6 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Twist Bioscience Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2018$50 MNo. 6$50 to $250 million

Twist Bioscience Corp: Raise no. 6, Mar 2018

Investors in this round

1 investor had bought by the notice of Apr 2, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Twist Bioscience Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $85 M offered; $35 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill Marine Peck · Executive Officer
  • Emily Marine Leproust · Executive Officer, Director
  • William Marine Banyai · Executive Officer, Director
  • Bob Marine Ragusa · Director
  • Fred Marine Craves · Director
  • Keith Marine Crandell · Director
  • Minqi Marine Li · Director
  • Paul Marine Conley · Director
  • Rob Marine Chess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emily Marine Leproust, President. Source: SEC Form D, newest notice filed Apr 2, 2018. Read the notice at the SEC.

equitySEC
Mar 2017$75 MNo. 5$50 to $250 million

Twist Bioscience Corp: Raise no. 5, Mar 2017

Investors in this round

63 investors had bought by the notice of Dec 29, 2017: 63 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Twist Bioscience Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$75 M of $75 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill Marine Peck · Executive Officer
  • Emily Marine Leproust · Executive Officer, Director
  • William Marine Banyai · Executive Officer, Director
  • Bob Marine Ragusa · Director
  • Fred Marine Craves · Director
  • Keith Marine Crandell · Director
  • Paul Marine Conley · Director
  • Rob Marine Chess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emily Marine Leproust, President. Source: SEC Form D and 3 amendments, newest notice filed Dec 29, 2017. Read the notice at the SEC.

equitySEC
Apr 2016$3 MIssued in a merger or acquisition$2 to $10 million

Twist Bioscience Corp: Private sale, Apr 2016

Investors in this round

46 investors had bought by the notice of Apr 19, 2016: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Twist Bioscience Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill James Peck · Executive Officer
  • Emily Marine Leproust · Executive Officer, Director
  • Solange James Glaize · Executive Officer
  • William Charles Banyai · Executive Officer, Director
  • Fred James Craves · Director
  • Keith James Crandell · Director
  • Nick James Naclerio · Director
  • Paul James Conley · Director
  • Rob James Chess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emily Marine Leproust, President. Source: SEC Form D, newest notice filed Apr 19, 2016. Read the notice at the SEC.

equitySEC
Jan 2016$61 MNo. 4$50 to $250 million

Twist Bioscience Corp: Raise no. 4, Jan 2016

Investors in this round

35 investors had bought by the notice of Jan 20, 2016: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Twist Bioscience Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$61 M of $61 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series D Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill James Peck · Executive Officer, Promoter
  • Emily Marine Leproust · Executive Officer, Director, Promoter
  • William Charles Banyai · Executive Officer, Director, Promoter
  • Fred James Craves · Director
  • Keith James Crandell · Director
  • Nick James Naclerio · Director
  • Paul James Conley · Director
  • Rob James Chess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emily Marine Leproust, President. Source: SEC Form D, newest notice filed Jan 20, 2016. Read the notice at the SEC.

equitySEC
May 2015$37 MNo. 3$10 to $50 million

Twist Bioscience Corp: Raise no. 3, May 2015

Investors in this round

28 investors had bought by the notice of Jun 11, 2015: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Twist Bioscience Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M of $37 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill James Peck · Executive Officer, Promoter
  • Emily Marine Leproust · Executive Officer, Director, Promoter
  • William Charles Banyai · Executive Officer, Director, Promoter
  • Fred James Craves · Director
  • Keith James Crandell · Director
  • Paul James Conley · Director
  • Rob James Chess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emily Marine Leproust, President. Source: SEC Form D, newest notice filed Jun 11, 2015. Read the notice at the SEC.

equitySEC
May 2014$26 MNo. 2$10 to $50 million

Twist Bioscience Corp: Raise no. 2, May 2014

Investors in this round

24 investors had bought by the notice of May 28, 2014: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Twist Bioscience Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $27 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill James Peck · Executive Officer
  • Emily Marine Leproust · Executive Officer, Director
  • William Charles Banyai · Executive Officer, Director
  • Fred James Craves · Director
  • Keith James Crandell · Director
  • Paul James Conley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The actual Total Offering Amount was $26,500,000.03 and the actual Total Amount Sold was $25,999,998.55”

Signed by Emily Marine Leproust, President. Source: SEC Form D, newest notice filed May 28, 2014. Read the notice at the SEC.

equitySEC
Jul 2013$9 MNo. 1$2 to $10 million

Twist Bioscience Corp: Raise no. 1, Jul 2013

Investors in this round

16 investors had bought by the notice of Feb 10, 2014: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Twist Bioscience Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A Preferred Stock
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill James Peck · Executive Officer
  • Emily Marine Leproust · Executive Officer, Director
  • William Charles Banyai · Executive Officer, Director
  • Keith James Crandell · Director
  • Paul James Conley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The actual Total Offering Amount was $9,298,570.76 and the actual Total Amount Sold was $9,110,713.27”

Signed by Emily Leproust, President. Source: SEC Form D and 1 amendment, newest notice filed Feb 10, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Twist Bioscience Corporation, its revenue in fiscal 2025 came from these product and service lines: NGS tools $208.10 million (55%), Synthetic genes $113.60 million (30%), Antibody discovery $23.45 million (6%), Oligo pools $20.23 million (5%), DNA libraries $11.18 million (3%).

    Annual report (SEC XBRL) · Sep 2025

  • Twist Bioscience Corp chose not to state its revenue in its newest notice of a funding round (Apr 2018).

    SEC Form D · Apr 2018

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Apr 2018

Products and services#

No products or services of Twist Bioscience Corp are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Twist Bioscience Corp
InvestorKindAmountRoundRoleSource
ARCH Venture Fund VIII Overage, L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Arch Venture Fund VII LPVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
ARCH Venture Partners VIII, LLCVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
ARCH Venture Partners VII, LLCVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
ARCH Venture Partners VII, L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Ever Alpha Fund L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 63 investors.

Largest shareholders today

Institutions holding Twist Bioscience Corporation shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Twist Bioscience Corp
NameRoleNamed in
Bill Marine PeckExecutive officerApr 2018
Emily Marine LeproustExecutive officerApr 2018
William Marine BanyaiExecutive officerApr 2018
Solange Marine GlaizeExecutive officerJun 2017
Bill James PeckExecutive officerApr 2016
Solange James GlaizeExecutive officerApr 2016
William Charles BanyaiExecutive officerApr 2016
Bob Marine RagusaDirectorApr 2018
Emily Marine LeproustDirectorApr 2018
Fred Marine CravesDirectorApr 2018
Keith Marine CrandellDirectorApr 2018
Minqi Marine LiDirectorApr 2018
Paul Marine ConleyDirectorApr 2018
Rob Marine ChessDirectorApr 2018
William Marine BanyaiDirectorApr 2018
Fred James CravesDirectorApr 2016
Keith James CrandellDirectorApr 2016
Nick James NaclerioDirectorApr 2016
Paul James ConleyDirectorApr 2016
Rob James ChessDirectorApr 2016
William Charles BanyaiDirectorApr 2016
Bill James PeckPromoterJan 2016
Emily Marine LeproustPromoterJan 2016
William Charles BanyaiPromoterJan 2016

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.